AIM: This study evaluated the prognostic implications of aVR ST elevation during ST elevation acute myocardial infarction (AMI). METHODS AND RESULTS: The Hirulog and Early Reperfusion/Occlusion-2 study randomized 17 073 patients with acute ST elevation AMI within 6 h of symptom onset to receive eitherbivalirudin or heparin, in addition to streptokinase and aspirin. The treatments had no effect on the primary endpoint of 30-day mortality. Electrocardiographic recordings were performed at randomization and at 60 min after commencing streptokinase. aVR ST elevation > or =1 mm was associated with higher 30-day mortality in 15 315 patients with normal intraventricular conduction regardless of AMI location (14.7% vs. 11.2% for anterior AMI, P = 0.0045 and 16.0% vs. 6.4% for inferior AMI, P < 0.0001). After adjusting for summed ST elevation and ST depression in other leads, associations with higher mortality were found with aVR ST elevation of > or =1.5 mm for anterior [odds ratio 1.69 (95% CI 1.16 to 2.45)] and of > or =1 mm for inferior AMI [odds ratio 2.41 (95% CI 1.76 to 3.30)]. There was a significant interaction between aVR ST elevation and infarct location. Thirty-day mortality was similar with anterior and inferior AMI when aVR ST elevation was present (11.5% vs. 13.2%, respectively, P = 0.51 with 1 mm and 23.5% vs. 22.5% respectively, P = 0.84 with > or = 1.5 mm ST elevation). After fibrinolytic therapy, resolution of ST elevation in aVR to <1 mm was associated with lower mortality, while new ST elevation > or =1 mm was associated with higher mortality. CONCLUSION:aVR ST elevation is an important adverse prognostic sign in AMI.
RCT Entities:
AIM: This study evaluated the prognostic implications of aVR ST elevation during ST elevation acute myocardial infarction (AMI). METHODS AND RESULTS: The Hirulog and Early Reperfusion/Occlusion-2 study randomized 17 073 patients with acute ST elevation AMI within 6 h of symptom onset to receive either bivalirudin or heparin, in addition to streptokinase and aspirin. The treatments had no effect on the primary endpoint of 30-day mortality. Electrocardiographic recordings were performed at randomization and at 60 min after commencing streptokinase. aVR ST elevation > or =1 mm was associated with higher 30-day mortality in 15 315 patients with normal intraventricular conduction regardless of AMI location (14.7% vs. 11.2% for anterior AMI, P = 0.0045 and 16.0% vs. 6.4% for inferior AMI, P < 0.0001). After adjusting for summed ST elevation and ST depression in other leads, associations with higher mortality were found with aVR ST elevation of > or =1.5 mm for anterior [odds ratio 1.69 (95% CI 1.16 to 2.45)] and of > or =1 mm for inferior AMI [odds ratio 2.41 (95% CI 1.76 to 3.30)]. There was a significant interaction between aVR ST elevation and infarct location. Thirty-day mortality was similar with anterior and inferior AMI when aVR ST elevation was present (11.5% vs. 13.2%, respectively, P = 0.51 with 1 mm and 23.5% vs. 22.5% respectively, P = 0.84 with > or = 1.5 mm ST elevation). After fibrinolytic therapy, resolution of ST elevation in aVR to <1 mm was associated with lower mortality, while new ST elevation > or =1 mm was associated with higher mortality. CONCLUSION: aVR ST elevation is an important adverse prognostic sign in AMI.
Authors: J A de Lemos; E M Antman; R P Giugliano; D A Morrow; C H McCabe; S S Cutler; A Charlesworth; R Schröder; E Braunwald Journal: Am J Cardiol Date: 2000-12-01 Impact factor: 2.778
Authors: H Yamaji; K Iwasaki; S Kusachi; T Murakami; R Hirami; H Hamamoto; K Hina; T Kita; N Sakakibara; T Tsuji Journal: J Am Coll Cardiol Date: 2001-11-01 Impact factor: 24.094
Authors: D J Engelen; A P Gorgels; E C Cheriex; E D De Muinck; A J Ophuis; W R Dassen; J Vainer; V G van Ommen; H J Wellens Journal: J Am Coll Cardiol Date: 1999-08 Impact factor: 24.094
Authors: Y Birnbaum; G S Wagner; G I Barbash; K Gates; D A Criger; S Sclarovsky; R J Siegel; C B Granger; J S Reiner; A M Ross Journal: Am J Cardiol Date: 1999-01-15 Impact factor: 2.778
Authors: R David Anderson; Harvey D White; E Magnus Ohman; Galen S Wagner; Mitchell W Krucoff; Paul W Armstrong; W Douglas Weaver; W Brian Gibler; Amanda L Stebbins; Robert M Califf; Eric J Topol Journal: Am Heart J Date: 2002-07 Impact factor: 4.749
Authors: Fernando A Cura; Marco Roffi; Narcis Pasca; Katherine E Wolski; A Michael Lincoff; Eric J Topol; Michael S Lauer Journal: Am J Cardiol Date: 2004-10-01 Impact factor: 2.778
Authors: Harvey D White; Cheuk-Kit Wong; Wanzhen Gao; Aaron Lin; Jocelyne Benatar; Philip Eg Aylward; John K French; Ralph A Stewart Journal: Eur Heart J Acute Cardiovasc Care Date: 2012-09
Authors: James McKinney; Ian Pitcher; Christopher B Fordyce; Masoud Yousefi; Tee Joo Yeo; Andrew Ignaszewski; Saul Isserow; Sammy Chan; Krishnan Ramanathan; Carolyn M Taylor Journal: PLoS One Date: 2016-07-28 Impact factor: 3.240